GH Research PLC (GHRS) 10-Year Financial Performance & Capital Metrics

GHRS • • Industrial / General

HealthcareBiotechnologyNeurology & CNS DisordersPsychiatric & CNS Disorders

AboutGH Research PLC, a clinical-stage biopharmaceutical company, engages in developing various therapies for the treatment of psychiatric and neurological disorders. The company focuses on developing 5-Methoxy-N,N-Dimethyltryptamine (5-MeO-DMT) therapies for the treatment of patients with treatment-resistant depression (TRD). Its lead program is GH001, an inhalable 5-MeO-DMT product candidate that has completed two Phase 1 clinical trials and Phase 1/2 clinical trial in patients with TRD. The company also develops GH002, an injectable 5-MeO-DMT product candidate; and GH003, an intranasal 5-MeO-DMT product candidate, which are in preclinical development trials with a focus on psychiatric and neurological disorders. GH Research PLC was incorporated in 2018 and is based in Dublin, Ireland.Show more

Revenue $0
EBITDA -$50M -22.2%
Net Income -$39M -9.5%
EPS (Diluted) -0.75 -10.3%
Gross Margin -
EBITDA Margin -
Operating Margin -
Net Margin -
ROE -19.58% -29.0%
ROIC -34.26% -24.9%
Debt/Equity 0.00 -21.6%
Interest Coverage -70.17 -23.1%

Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

✓Company is almost debt free

✗Weaknesses

✗Weak Piotroski F-Score: 1/9
✗Low asset turnover indicates capital-intensive operations

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y-

5Y-

3Y-

TTM-

Profit (Net Income) CAGR

10Y-

5Y-

3Y-

TTM-3.6%

EPS CAGR

10Y-

5Y-

3Y-

TTM7.5%

ROCE

10Y Avg-26.21%

5Y Avg-15.95%

3Y Avg-18.13%

Latest-25.22%

Peer Comparison

Psychiatric & CNS Disorders

Name	Market Cap	Current Price	P/E Ratio	Revenue Growth 1Y	Net Margin	ROE	FCF Yield	Debt/Equity
JAZZJazz Pharmaceuticals plc	10.4B	171.16	19.79	6.12%	-8.86%	-9.31%	12.96%	1.51
ACADACADIA Pharmaceuticals Inc.	4.49B	26.53	19.51	31.85%	24.94%	28.47%	3.5%	0.07
CPRXCatalyst Pharmaceuticals, Inc.	2.82B	22.96	17.53	23.49%	37.63%	23.64%	8.48%	0.00
HRMYHarmony Biosciences Holdings, Inc.	2.1B	36.41	14.51	22.8%	22.48%	22.23%	10.43%	0.28
ALKSAlkermes plc	5.15B	31.22	14.39	-6.36%	22.27%	19.55%	7.87%	0.05
PRTCPureTech Health plc	463.31M	19.17	9.59	44.98%	-495.91%	-8.53%		0.05
LBRXLB Pharmaceuticals Inc Common Stock	540.89M	21.38	-1.20
NMRANeumora Therapeutics, Inc. Common Stock	361.97M	2.13	-1.39			-178.79%		0.01

Profit & Loss

	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Sales/Revenue+	0	0	0	0	0	0
Revenue Growth %	-	-	-	-	-	-
Cost of Goods Sold+	0	0	0	0	0	0
COGS % of Revenue	-	-	-	-	-	-
Gross Profit+	0	0	0	0	0	0
Gross Margin %	-	-	-	-	-	-
Gross Profit Growth %	-	-	-	-	-	-
Operating Expenses+	310K	446K	15.1M	30.55M	41.22M	50.31M
OpEx % of Revenue	-	-	-	-	-	-
Selling, General & Admin	14K	108K	6.54M	10.06M	11.12M	15M
SG&A % of Revenue	-	-	-	-	-	-
Research & Development	296K	338K	8.55M	20.48M	29.82M	35.02M
R&D % of Revenue	-	-	-	-	-	-
Other Operating Expenses	0	0	5K	14K	280K	294K
Operating Income+	-310K	-446K	-15.1M	-30.55M	-41.22M	-50.31M
Operating Margin %	-	-	-	-	-	-
Operating Income Growth %	-	-0.44%	-32.86%	-1.02%	-0.35%	-0.22%
EBITDA+	0	0	-15.08M	-30.51M	-40.91M	-50M
EBITDA Margin %	-	-	-	-	-	-
EBITDA Growth %	-	-	-	-1.02%	-0.34%	-0.22%
D&A (Non-Cash Add-back)	310K	446K	19K	47K	315K	315K
EBIT	-310K	-446K	-9.19M	-22.46M	-35.52M	-38.91M
Net Interest Income+	0	0	-8.99K	0	1.17M	1.91M
Interest Income	0	0	9	-	1.89M	2.63M
Interest Expense	0	0	9K	-	723K	717K
Other Income/Expense	0	0	5.9M	8.1M	5.63M	11.35M
Pretax Income+	-310K	-446K	-9.2M	-22.46M	-35.59M	-38.96M
Pretax Margin %	-	-	-	-	-	-
Income Tax+	0	0	0	0	0	0
Effective Tax Rate %	1%	1%	1%	1%	1%	1%
Net Income+	-310K	-446K	-9.2M	-22.46M	-35.59M	-38.96M
Net Margin %	-	-	-	-	-	-
Net Income Growth %	-	-0.44%	-19.63%	-1.44%	-0.58%	-0.09%
Net Income (Continuing)	-310K	-446K	-9.2M	-22.46M	-35.59M	-38.96M
Discontinued Operations	0	0	0	0	0	0
Minority Interest	0	0	0	0	0	0
EPS (Diluted)+	-0.01	-0.01	-0.18	-0.14	-0.68	-0.75
EPS Growth %	-	-0.32%	-11.24%	0.22%	-3.86%	-0.1%
EPS (Basic)	-0.01	-0.01	-0.18	-0.14	-0.68	-0.75
Diluted Shares Outstanding	28M	30.37M	52.02M	52.02M	52.02M	52.03M
Basic Shares Outstanding	28M	30.37M	52.02M	52.02M	52.02M	52.03M
Dividend Payout Ratio	-	-	-	-	-	-

Balance Sheet

	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Total Current Assets+	504K	5.91M	279.84M	168.54M	164.09M	154.22M
Cash & Short-Term Investments	498K	5.89M	276.78M	165.96M	161.56M	149.32M
Cash Only	498K	5.89M	276.78M	165.96M	78.42M	100.79M
Short-Term Investments	0	0	0	0	83.14M	48.53M
Accounts Receivable	0	0	48K	90K	178K	1.73M
Days Sales Outstanding	-	-	-	-	-	-
Inventory	0	-6K	3.01M	-90K	0	0
Days Inventory Outstanding	-	-	-	-	-	-
Other Current Assets	6K	11K	10K	47K	119K	0
Total Non-Current Assets+	0	0	82K	85.82M	62.21M	34.05M
Property, Plant & Equipment	0	0	82K	97K	1.07M	748K
Fixed Asset Turnover	-	-	-	-	-	-
Goodwill	0	0	0	0	0	0
Intangible Assets	0	0	0	0	0	0
Long-Term Investments	0	0	0	85.72M	61.14M	33.3M
Other Non-Current Assets	0	0	0	0	0	0
Total Assets+	504K	5.91M	279.92M	254.36M	226.3M	188.27M
Asset Turnover	-	-	-	-	-	-
Asset Growth %	-	10.73%	46.35%	-0.09%	-0.11%	-0.17%
Total Current Liabilities+	104K	246K	2.75M	4.55M	6.7M	8.95M
Accounts Payable	93K	1K	883K	1.87M	0	0
Days Payables Outstanding	-	-	-	-	-	-
Short-Term Debt	0	0	0	0	343K	255K
Deferred Revenue (Current)	0	0	0	0	0	0
Other Current Liabilities	0	0	168K	312K	6.36M	8.7M
Current Ratio	4.85x	24.03x	101.80x	37.07x	24.49x	17.23x
Quick Ratio	4.85x	24.06x	100.70x	37.09x	24.49x	17.23x
Cash Conversion Cycle	-	-	-	-	-	-
Total Non-Current Liabilities+	0	0	0	1.87M	631K	369K
Long-Term Debt	0	0	0	0	0	0
Capital Lease Obligations	0	0	0	0	631K	369K
Deferred Tax Liabilities	0	0	0	0	0	0
Other Non-Current Liabilities	0	0	0	0	0	0
Total Liabilities	104K	246K	2.75M	4.55M	7.33M	9.32M
Total Debt+	0	0	0	0	974K	624K
Net Debt	-498K	-5.89M	-276.78M	-165.96M	-77.45M	-100.17M
Debt / Equity	-	-	-	-	0.00x	0.00x
Debt / EBITDA	-	-	-	-	-	-
Net Debt / EBITDA	-	-	-	-	-	-
Interest Coverage	-	-	-1677.78x	-	-57.02x	-70.17x
Total Equity+	400K	5.67M	277.18M	249.82M	218.97M	178.95M
Equity Growth %	-	13.16%	47.92%	-0.1%	-0.12%	-0.18%
Book Value per Share	0.01	0.19	5.33	4.80	4.21	3.44
Total Shareholders' Equity	400K	5.67M	277.18M	249.82M	218.97M	178.95M
Common Stock	801K	871K	1.3M	1.3M	1.3M	1.3M
Retained Earnings	-389K	-835K	-10.04M	-32.49M	-67.94M	-106.45M
Treasury Stock	0	0	0	0	0	0
Accumulated OCI	-12K	200K	-5.54M	-10.44M	-5.86M	-7.37M
Minority Interest	0	0	0	0	0	0

Cash Flow

	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Cash from Operations+	-289K	-330K	-15.28M	-26.2M	-33.34M	-42.28M
Operating CF Margin %	-	-	-	-	-	-
Operating CF Growth %	-	-0.14%	-45.31%	-0.71%	-0.27%	-0.27%
Net Income	-310K	-446K	-9.2M	-22.46M	-35.59M	-38.96M
Depreciation & Amortization	0	0	19K	47K	315K	315K
Stock-Based Compensation	0	0	366K	1.67M	2.29M	1.17M
Deferred Taxes	0	0	-5.92M	0	0	0
Other Non-Cash Items	0	0	9K	-7.62M	-2M	-5M
Working Capital Changes	21K	116K	-559K	2.16M	1.65M	188K
Change in Receivables	0	0	0	0	0	0
Change in Inventory	0	0	0	0	0	0
Change in Payables	0	0	0	0	0	0
Cash from Investing+	0	0	-104K	-84.69M	-54.1M	65.14M
Capital Expenditures	0	0	-104K	-67K	-100K	-49K
CapEx % of Revenue	-	-	-	-	-	-
Acquisitions	-	-	-	-	-	-
Investments	-	-	-	-	-	-
Other Investing	0	0	0	0	0	0
Cash from Financing+	797K	5.5M	286.45M	0	-204K	-304K
Debt Issued (Net)	-	-	-	-	-	-
Equity Issued (Net)	-	-	-	-	-	-
Dividends Paid	0	0	0	0	0	0
Share Repurchases	-	-	-	-	-	-
Other Financing	0	0	-22.75M	0	0	0
Net Change in Cash	-	-	-	-	-	-
Free Cash Flow+	-289K	-330K	-15.39M	-26.27M	-33.44M	-42.33M
FCF Margin %	-	-	-	-	-	-
FCF Growth %	-	-0.14%	-45.63%	-0.71%	-0.27%	-0.27%
FCF per Share	-0.01	-0.01	-0.30	-0.50	-0.64	-0.81
FCF Conversion (FCF/Net Income)	0.93x	0.74x	1.66x	1.17x	0.94x	1.09x
Interest Paid	0	0	0	0	0	0
Taxes Paid	0	0	0	0	0	0

Key Ratios

Metric	2019	2020	2021	2022	2023	2024
Return on Equity (ROE)	-77.5%	-14.7%	-6.51%	-8.52%	-15.18%	-19.58%
Return on Invested Capital (ROIC)	-	-	-13323.53%	-54.39%	-27.43%	-34.26%
Debt / Equity	-	-	-	-	0.00x	0.00x
Interest Coverage	-	-	-1677.78x	-	-57.02x	-70.17x
FCF Conversion	0.93x	0.74x	1.66x	1.17x	0.94x	1.09x

Frequently Asked Questions

Growth & Financials

GH Research PLC (GHRS) grew revenue by 0.0% over the past year. Growth has been modest.

GH Research PLC (GHRS) reported a net loss of $42.9M for fiscal year 2024.

Dividend & Returns

GH Research PLC (GHRS) has a return on equity (ROE) of -19.6%. Negative ROE indicates the company is unprofitable.

GH Research PLC (GHRS) had negative free cash flow of $42.6M in fiscal year 2024, likely due to heavy capital investments.

← Back to Screener